 |
Medscape Conference Coverage, based on selected sessions at: The Liver Meeting 2007: 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) November 2 - 6, 2007, Boston, Massachusetts This activity is not sanctioned by, nor a part of, the American Association for the Study of Liver Diseases.
Topic Overviews- CME Viral Hepatitis
Physicians - maximum of 1.25 AMA PRA Category 1 credit(s)™ - Update on Chronic Hepatitis B
Kris V. Kowdley, MD, FACP - Hepatitis C: Where Are We and Where Are We Going?
Tram T. Tran, MD
- CME Complications of Cirrhosis
Physicians - maximum of 1.0 AMA PRA Category 1 credit(s)™ - Complications of Cirrhosis -- Clinical Insights and Implications for Practice
Steven K. Herrine, MD - HCC -- Current Concepts and Considerations
Alex S. Befeler, MD
- CME Select Topics in Liver Disease -- Advances in Alcoholic Liver Disease and NAFLD
Physicians - maximum of 1.25 AMA PRA Category 1 credit(s)™ - Alcohol-Induced Liver Injury
Willis C. Maddrey, MD - Nonalcoholic Fatty Liver Disease -- New Insight Into Old Questions
William F. Balistreri, MD
Expert InterviewsDaily Session Coverage | Evolving Issues in Viral HepatitisNancy Reau, MD, assesses the latest information regarding the management and clinical evaluation of patients with chronic hepatitis C and B, as based on data presented at AASLD 2007. |
 | New Directions in Pediatric Liver DiseaseWhat's the latest thinking regarding treatment of the pediatric patient with liver disease? William Balistreri, MD, explores the issues, based on selected sessions at AASLD 2007. |
Conference News- CME NAFLD Is a Risk Factor for Diabetes, Metabolic SyndromeIndividuals with nonalcoholic fatty liver disease and increased serum alanine transferase levels along with other risk factors are at increased risk of developing diabetes and metabolic syndrome.
Medscape Medical News, November 15, 2007 - Telaprevir Continues to Prove Its Potency Against HCVWhen used with pegylated interferon alfa-2a and ribavirin, the hepatitis C virus protease inhibitor telaprevir could shorten treatment duration, according to findings from the PROVE 2 trial.
Medscape Medical News, November 13, 2007 - CME Tenofovir Significantly More Effective Than Adefovir Against HBVTenofovir, a drug intended to treat HIV infection, is better than adefovir, a drug intended to treat hepatitis B virus infection.
Medscape Medical News, November 12, 2007 - NAC Slows Early-Stage Non-Acetaminophen-Related Liver FailureIf given early, intravenous N-acetylcysteine, used to treat acetaminophen poisoning, is helpful for acute liver failure resulting from hepatitis B and drug-induced injury, among other causes.
Medscape Medical News, November 12, 2007 - CME Entecavir Shows High HBV Suppression, Low Resistance in Long-Term StudiesA 4-year follow-up by the drug's maker finds entecavir effective, even for patients who did not respond after 1 year.
Medscape Medical News, November 9, 2007 - CME Tenofovir Works for Experienced HBV-Infected PatientsThose patients with hepatitis B virus infection who were previously treated with other drugs still respond well to tenofovir, commonly used to treat HIV infection.
Medscape Medical News, November 8, 2007 - CME HALT-C Trial Gets Negative ResultsMaintenance therapy with peginterferon failed to halt liver disease progression in patients infected with hepatitis C virus.
Medscape Medical News, November 7, 2007 - Tumor Down-Staging for Hepatocellular Carcinoma Has Good ResultsAfter their tumors were down-staged to enable liver transplantation, 92 patients with HCC were alive at 4 years.
Medscape Medical News, November 7, 2007 - CME Donor Risk Must Be Factored Into Transplant DecisionsThe increased use of expanded criteria donor livers raises the issue of who should receive them.
Medscape Medical News, November 6, 2007 - Imaging May Help Diagnose Hepatic EncephalopathyResearchers in Japan find that near-infrared spectroscopy, which measures brain function, might help identify mild or asymptomatic cases of hepatic encephalopathy.
Medscape Medical News, November 5, 2007
|
Legal DisclaimerThe materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Association for the Study of Liver Diseases. These materials and the related activity are not sanctioned by the American Association for the Study of Liver Diseases or the commercial supporter of the conference and do not constitute an official part of that conference. Copyright © 2007 Medscape. |
|
|
